Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX) Share Price

Price 0.31p on 08-01-2026 at 19:10:07
Change -0.005p -1.59%
Buy 0.32p
Sell 0.30p
Last Trade: Buy 375.00 at 0.32p
Day's Volume: 4,862,741
Last Close: 0.31p
Open: 0.315p
ISIN: GB00BYW79Y38
Day's Range 0.31p - 0.315p
52wk Range: 0.045p - 0.53p
Market Capitalisation: £6.54m
VWAP: 0.310018p
Shares in Issue: 2.11b

Nuformix (NFX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 375 0.32p Ordinary
16:29:38 - 08-Jan-26
Buy* 18,790 0.32p Ordinary
15:37:49 - 08-Jan-26
Sell* 13,643 0.30p Ordinary
15:14:12 - 08-Jan-26
Buy* 314,484 0.3164p Ordinary
13:25:07 - 08-Jan-26
Buy* 200,000 0.316p Ordinary
13:15:18 - 08-Jan-26
Sell* 54,723 0.302p Ordinary
13:06:29 - 08-Jan-26
Sell* 21,922 0.30p Ordinary
12:36:17 - 08-Jan-26
Sell* 167,243 0.3033p Ordinary
12:29:30 - 08-Jan-26
Sell* 500,000 0.3033p Ordinary
12:14:08 - 08-Jan-26
Sell* 126,211 0.3033p Ordinary
11:48:11 - 08-Jan-26
See more Nuformix trades

Nuformix (NFX) Share Price History

Time period:
to
Date Open High Low Close Volume
8th Jan 2026 (Thu) 0.315 0.315 0.31 0.31 4,862,741
7th Jan 2026 (Wed) 0.335 0.335 0.315 0.315 14,784,223
6th Jan 2026 (Tue) 0.34 0.34 0.335 0.335 24,334,467
5th Jan 2026 (Mon) 0.32 0.34 0.295 0.34 54,314,377
2nd Jan 2026 (Fri) 0.255 0.305 0.25 0.295 33,273,118
1st Jan 2026 (Thu) 0.255 0.255 0.255 0.255 0
31st Dec 2025 (Wed) 0.245 0.255 0.245 0.255 3,006,285
30th Dec 2025 (Tue) 0.25 0.25 0.245 0.245 8,090,693
29th Dec 2025 (Mon) 0.255 0.26 0.245 0.25 8,448,744
26th Dec 2025 (Fri) 0.255 0.255 0.255 0.255 0
25th Dec 2025 (Thu) 0.255 0.255 0.255 0.255 0
24th Dec 2025 (Wed) 0.225 0.255 0.225 0.255 9,807,656
23rd Dec 2025 (Tue) 0.225 0.225 0.225 0.225 3,378,486
22nd Dec 2025 (Mon) 0.24 0.241 0.241 0.241 10,171,645
19th Dec 2025 (Fri) 0.24 0.24 0.24 0.24 7,137,589
18th Dec 2025 (Thu) 0.25 0.25 0.24 0.24 8,980,050
17th Dec 2025 (Wed) 0.25 0.25 0.24 0.25 8,056,044
16th Dec 2025 (Tue) 0.27 0.27 0.25 0.25 4,757,311
15th Dec 2025 (Mon) 0.265 0.2875 0.265 0.27 22,283,690
12th Dec 2025 (Fri) 0.21 0.285 0.21 0.265 75,998,075
11th Dec 2025 (Thu) 0.236 0.25 0.185 0.21 93,282,477
10th Dec 2025 (Wed) 0.255 0.251 0.25 0.25 5,704,925
9th Dec 2025 (Tue) 0.255 0.255 0.245 0.255 1,233,924
8th Dec 2025 (Mon) 0.255 0.255 0.25 0.255 12,317,113
See more Nuformix price history

Nuformix (NFX) Regulatory News

Date Source Headline
28th Nov 2025 3:22 pm RNS Total Voting Rights
12th Nov 2025 7:01 am RNS Update re. US FDA ODD Application
12th Nov 2025 7:00 am RNS Results of Underwritten Open Offer
28th Oct 2025 7:00 am RNS Underwritten Open Offer
10th Oct 2025 7:00 am RNS Change of Auditor
25th Sep 2025 7:00 am RNS-R European Respiratory Society Congress Attendance
11th Aug 2025 7:00 am RNS US FDA ODD Application Submitted for NXP002
30th May 2025 2:24 pm RNS Total Voting Rights
29th May 2025 7:00 am RNS Confirmation of European ODD for NXP002
23rd May 2025 1:08 pm RNS Publication of a Prospectus
See more Nuformix regulatory news

Nuformix (NFX) Share News

IN BRIEF: Nuformix raises GBP228,000 in open offer

12th Nov 2025 16:59

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Raises approximately GBP228,081 through an underwritten open offer at an issue price of 0.2 pence per share. Valid acceptances were received from qualifying shareholders for 465.8 million shares, representing more than four times the 114.0 million shares available. The full amount of 114.0 million shares will be issued in connection with the open offer. Company says applications for open offer shares under the excess application facility will be scaled back on a pro-rata basis. Expects dealings in the new shares to commence in London on Thursday. Read More

TRADING UPDATES: Celsius raises funds; Built Cybernetics acquisition

12th Nov 2025 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: Nuformix submits FDA drug designation application for NXP002

11th Aug 2025 12:11

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Read More

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

See more Nuformix news
FTSE 100 Latest
Value10,044.69
Change-3.52

Login to your account

Forgot Password?

Not Registered